Table 5 Predictors of TSH normalization among hyperthyroid patients attending UoGCSH
Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
CHR (95% CI) | p-value | AHR (95% CI) | p-value | ||
Age (years) | 0.987 [0.970–1.005] | 0.151 | 0.967 [0.937–0.998] | 0.036 | |
Gender | Female | 0.992 [0.359–2.379] | 0.988 | – | – |
Etiology | GD | 1 | 1 | ||
TMNG | 0.343 [0.141–0.836] | 0.019 | 0.580 [0.147–2.287] | 0.436 | |
Toxic nodular goiter | 0.415 [0.166–1.038] | 0.060 | 0.872 [0.218–3.499] | 0.847 | |
Duration of symptoms before treatment (months) | 0.998 [0.996–1.000] | 0.141 | 1.000 [0.997–1.002] | 0.708 | |
WHO goiter size | 0 | 1 | 1 | ||
I | 0.248 [0.030–2.024] | 0.193 | – | – | |
II | 0.356 [0.047–2.676] | 0.315 | – | – | |
III | 0.336 [0.042–2.692] | 0.304 | – | – | |
Baseline TSH | 1.293 [0.891–1.874] | 0.175 | 1.214 [0.647–2.279] | 0.545 | |
Baseline FT4 | 0.993 [0.990–0.996] | 0.000 | 0.992 [0.988–0.997] | 0.000 | |
Baseline T3 | 0.907 [0.797–1.033] | 0.142 | 0.966 [0.887–1.051] | 0.418 | |
PTU dose: initial | 1.001 [0.999–1.004] | 0.246 | 1.001 [0.999–1.004] | 0.289 | |
PTU dose: Maintenance | 0.999 [0.995–1.004] | 0.832 | 0.999 [0.994–1.004] | 0.662 | |